News from eli lilly and company A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

Jun 25, 2020, 08:00 ET Central Indiana Racial Equity Fund Launches with more than $2.2 Million in Initial Commitments

A coalition of local stakeholders has established the Central Indiana Racial Equity Fund with an initial investment of more than $2.2 million to...


Jun 24, 2020, 08:30 ET Lilly launches program about what people with diabetes should "Know Before the Low™"

About 34 million Americans live with diabetes, and some are at risk of low blood sugar and very low blood sugar emergencies (severe hypoglycemia).1...


Jun 19, 2020, 12:25 ET Full results from EMPERIAL exercise ability trials presented

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced full results from the EMPERIAL-Reduced and EMPERIAL-Preserved trials...


Jun 17, 2020, 06:45 ET Emgality® Demonstrates Reduction in Frequency, Duration, and Pain Severity in Patients with Episodic and Chronic Migraine

Emgality® (galcanezumab-gnlm) reduces total pain burden in a recent analysis of patients with episodic and chronic migraine. Total pain burden is a...


Jun 16, 2020, 11:00 ET Lilly's OVERCOME Study Reveals Less than 30 Percent of People Living with Migraine Take Recommended Prescription Medications

Eli Lilly and Company (NYSE: LLY) announced today that less than 30 percent of people with migraine are taking a recommended prescription medication, ...


Jun 16, 2020, 06:45 ET Verzenio® (abemaciclib) Significantly Reduced the Risk of Cancer Returning in People with High Risk HR+, HER2- Early Breast Cancer

Eli Lilly and Company (NYSE: LLY) today announced Verzenio® (abemaciclib) in combination with standard adjuvant endocrine therapy (ET) has met the...


Jun 15, 2020, 22:21 ET FDA approves Lyumjev™ (insulin lispro-aabc injection), Lilly's new rapid-acting insulin

The U.S. Food and Drug Administration (FDA) has approved Lyumjev™ (insulin lispro-aabc injection, 100 units/mL and 200 units/mL), Eli Lilly and...


Jun 15, 2020, 06:45 ET Lilly Begins a Phase 3 Clinical Trial with Baricitinib for Hospitalized COVID-19 Patients

Eli Lilly and Company (NYSE: LLY) announced today that the first patient has been enrolled in a Phase 3 randomized, double-blind, placebo–controlled...


Jun 13, 2020, 11:15 ET Once-weekly Trulicity® (dulaglutide) demonstrates significantly higher adherence and more persistence compared to once-weekly semaglutide and exenatide injections

New real-world data showed Trulicity® (dulaglutide) had significantly higher adherence and longer persistence compared to weekly injections of...


Jun 13, 2020, 11:00 ET Eli Lilly and Company Foundation Pledges $25 Million to Combat Racial Injustice

Eli Lilly and Company (NYSE: LLY) and the Lilly Foundation announced today a pledge of $25 million and 25,000 volunteer hours over five years to...


Jun 12, 2020, 15:46 ET Lilly and Dermira Present New Lebrikizumab Phase 2b Clinical Data Showing Patients with Atopic Dermatitis Had Clinically Meaningful Improvements in Itch, Sleep and Quality of Life

Eli Lilly and Company (NYSE: LLY) and Dermira, Inc., a wholly-owned subsidiary of Eli Lilly and Company, presented new data from the Phase 2b...


Jun 12, 2020, 15:00 ET Lilly Highlights the Evolution of Its Dermatology Portfolio at Annual American Academy of Dermatology Meeting (AAD)

Eli Lilly and Company (NYSE: LLY) announced today that it will present new data from Taltz® (ixekizumab), Olumiant® (baricitinib), mirikizumab and...


Jun 12, 2020, 11:03 ET Lilly Partners with Indianapolis Recorder Newspaper, Radio One and WISH-TV for a Day of Solidarity Virtual Event

What: Eli Lilly and Company, Indianapolis Recorder Newspaper, Radio One and WISH-TV invite people and organizations to come together to acknowledge...


Jun 09, 2020, 06:45 ET First patient dose delivered for Lilly's tirzepatide cardiovascular outcomes trial

The first patient dose has been delivered in SURPASS-CVOT, the phase 3 cardiovascular outcomes trial for tirzepatide, Eli Lilly and Company's (NYSE:...


Jun 08, 2020, 11:00 ET Lilly to Participate in Goldman Sachs Global Healthcare Conference

Eli Lilly and Company (NYSE:LLY) will participate in the Goldman Sachs 41st Annual Global Healthcare Conference on Wednesday, June 10, 2020. Joshua...


Jun 08, 2020, 07:15 ET Lilly Announces Start of a Phase 1 Study for its Second Potential COVID-19 Antibody Treatment

Eli Lilly and Company (NYSE: LLY) announced today its partner Junshi Biosciences (HKEX: 1877) has dosed the first healthy volunteer in a study of a...


Jun 03, 2020, 06:45 ET EULAR 2020: Lilly's Taltz® (ixekizumab) Continues to Show Robust and Consistent Efficacy in Psoriatic Arthritis

Taltz® (ixekizumab) demonstrated consistent efficacy and long-term potential to help patients with psoriatic arthritis (PsA) in new data to be...


Jun 03, 2020, 06:45 ET EULAR 2020: Lilly Shares New Data for Olumiant® in Rheumatoid Arthritis and Systemic Lupus Erythematosus

Eli Lilly and Company (NYSE: LLY) will present new data for Olumiant® (baricitinib) at the virtual European Congress of Rheumatology (EULAR 2020)...


Jun 01, 2020, 06:45 ET Lilly's Taltz® (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)

Eli Lilly and Company (NYSE: LLY) announced today the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License...


Jun 01, 2020, 06:30 ET Lilly Begins World's First Study of a Potential COVID-19 Antibody Treatment in Humans

Eli Lilly and Company (NYSE: LLY) today announced patients have been dosed in the world's first study of a potential antibody treatment designed to...


May 29, 2020, 21:07 ET Lilly's CYRAMZA® (ramucirumab) Receives FDA Approval as First-Line Treatment for Metastatic EGFR-Mutated Non-Small Cell Lung Cancer

Eli Lilly and Company (NYSE: LLY) today announced that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA® (ramucirumab injection, 10...


May 28, 2020, 19:17 ET Lilly Receives U.S. FDA Approval of TAUVID™ (flortaucipir F 18 injection) for Use in Patients Being Evaluated for Alzheimer's Disease

TAUVID™, a radioactive diagnostic agent, has been approved by the FDA for positron emission tomography (PET) imaging of the brain to estimate the...


May 26, 2020, 17:51 ET Statement from Lilly Chairman and CEO Dave Ricks on New Part D Senior Savings Model

President Donald J. Trump and Seema Verma, Administrator for the Centers for Medicare & Medicaid Services, today announced details of the new Part D...


May 26, 2020, 08:00 ET Boehringer Ingelheim and Lilly to collaborate with Duke Clinical Research Institute on a pragmatic trial examining Jardiance's® effects following an acute myocardial infarction

Boehringer Ingelheim and Eli Lilly and Company (NYSE:LLY) today announced an academic research collaboration with the Duke Clinical Research...


May 26, 2020, 06:45 ET Emgality® Shows Improvement in Work Productivity and Health and Well-Being Between Attacks in Patients with Migraine and a History of Preventive Treatment Failure

Emgality® (galcanezumab-gnlm) significantly improved work productivity and reduced interictal burden, defined as health and well-being between...